CLINICAL TRIALS PROFILE FOR ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01516346 ↗ | Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction | Completed | National Institute on Aging (NIA) | Phase 2 | 2012-01-01 | The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy. |
| NCT01516346 ↗ | Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction | Completed | University of Pennsylvania | Phase 2 | 2012-01-01 | The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy. |
| NCT01516346 ↗ | Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction | Completed | Corporal Michael J. Crescenz VA Medical Center | Phase 2 | 2012-01-01 | The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy. |
| NCT01822808 ↗ | Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure | Unknown status | Momentum Research, Inc. | Phase 3 | 2013-01-01 | To investigate the effect of hydralazine isosorbide dinitrate on clinical outcomes, symptoms, cardiac parameters and functional status of African patients hospitalized with AHF and left ventricular dysfunction during 24 weeks of therapy. Administration of hydralazine/nitrates will be superior to placebo administration in reducing HF readmission or death, improving dyspnoea, reducing blood pressure and brain natriuretic peptide (BNP) in African patients admitted with AHF and left ventricular dysfunction. |
| NCT01822808 ↗ | Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure | Unknown status | University of Cape Town | Phase 3 | 2013-01-01 | To investigate the effect of hydralazine isosorbide dinitrate on clinical outcomes, symptoms, cardiac parameters and functional status of African patients hospitalized with AHF and left ventricular dysfunction during 24 weeks of therapy. Administration of hydralazine/nitrates will be superior to placebo administration in reducing HF readmission or death, improving dyspnoea, reducing blood pressure and brain natriuretic peptide (BNP) in African patients admitted with AHF and left ventricular dysfunction. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE
Sponsor Name
| Sponsor Name for ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | |
| Sponsor | Trials |
| University of Pennsylvania | 1 |
| Danish Council for Independent Research | 1 |
| Corporal Michael J. Crescenz VA Medical Center | 1 |
| [disabled in preview] | 2 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
